Clorox Co-The

Clorox’s Q2 earnings dip: revenue flat, EPS down, investors pull back—learn how the household‑cleaning brand is navigating margin pressure and market shifts.

Clorox’s Q2 earnings miss shows margin squeeze, regulatory pressure, and price‑war risks, yet highlights eco‑friendly growth and data‑driven pricing as key recovery paths.

Clorox institutional trades show a balanced mix of buying and selling—hedge funds and asset managers stay active yet unchanged on value, keeping the stock steady within its 52‑week range.

Clorox’s $2.25 B buy of GOJO expands its hygiene dominance to 55% of the U.S. hand‑sanitizer market, delivering $150‑$170 M cash flow and smart‑dispenser synergies—but the debt‑backed deal adds 0.4x leverage risk that investors must watch closely.

Clorox’s Q2 2026 webcast, new allergen‑neutraliser launch and ERP upgrade show the company’s focus on health‑conscious products, operational efficiency and dividend‑growth, even as analysts tighten price targets. Discover how these moves shape its n…

Clorox launches allergen‑neutralizing PURE™ sprays to tap growing indoor‑wellness trend, while a cloud‑based ERP upgrade targets cost cuts and margin recovery.

Clorox’s dividend allure clashes with earnings uncertainty as its ERP overhaul seeks to boost efficiency amid sector pressure.

Clorox Co. offers steady dividends but faces margin pressure, regulatory hurdles, and a growing shift toward green cleaning—can its brand adapt to win new markets?

Clorox shares steady in the mid‑hundreds, reflecting a solid consumer‑staples position but flat earnings; investors see limited upside without strategic shifts.

Clorox stock dips modestly to $101.32 on Dec 10, 2025, holding a 16.1x P/E and $12B market cap amid commodity pressures, sustainability pushes, and a stable consumer staples outlook.